Measurement of circulating neuron-specific enolase mRNA in diabetes mellitus

Annals of the New York Academy of Sciences

Volumn 1137, Issue , 2008, Pages 258-263

  Sandhu, H S ^a   Butt, A N ^a   Powrie, J ^a   Swaminathan, R ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Diabetes mellitus; Enolase; mRNA; Neuropathy; Retinopathy

Indexed keywords

BETA ACTIN; MESSENGER RNA; MOLECULAR MARKER; NEURON SPECIFIC ENOLASE;

ADULT; AGED; BLOOD SAMPLING; CELL PROLIFERATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PROLIFERATIVE RETINOPATHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

EID: 52249118786     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1448.044     Document Type: Conference Paper

References (17)

1. Butt, A.N. et al. 2006. Circulating nucleic acids and diabetic complications. Ann. N. Y. Acad. Sci. 1075 : 258 270.
2. Gooch, C. & D. Podwall. 2004. The diabetic neuropathies. Neurologist 10 : 311 322.
3. Pirart, J. 1977. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973 (third and last part). Diabetes Metab. 3 : 245 256.
4. Caputo, G.M. et al. 1994. Assessment and management of foot disease in patients with diabetes. N. Engl. J. Med. 331 : 854 860.
5. Holzer, S.E. et al. 1998. Costs and duration of care for lower extremity ulcers in patients with diabetes. Clin. Ther. 20 : 169 181.
6. Ollendorf, D.A. et al. 1998. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care 21 : 1240 1245.
7. Ramsey, S.D. et al. 1999. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 22 : 382 387.
8. Rith-Najarian, S. et al. 1998. Reducing lowerextremity amputations due to diabetes: application of the staged diabetes management approach in a primary care setting. J. Fam. Pract. 47 : 127 132.
9. Marangos, P.J. et al. 1979. Measurement of neuron-specific (NSE) and non-neuronal (NNE) isoenzymes of enolase in rat, monkey and human nervous tissue. J Neurochem. 33 : 319 329.
10. Kato, K. et al. 1982. Distribution of nervous system-specific forms of enolase in peripheral tissues. Brain Res. 237 : 441 448.
11. Kaiser, E. et al. 1989. Clinical biochemistry of neuron specific enolase. Clin. Chim. Acta 183 : 13 31.
12. Marangos, P.J. & D.E. Schmechel. 1987. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu. Rev. Neurosci. 10 : 269 295.
13. Ishiguro, Y. et al. 1983. Nervous system-specific enolase in serum as a marker for neuroblastoma. Pediatrics 72 : 696 700.
14. Stroun, M. et al. 1989. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46 : 318 322.
15. Rainer, T.H. et al. 2003. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin. Chem. 49 : 562 569.
16. Lo, Y.M. et al. 2000. Plasma DNA as a prognostic marker in trauma patients. Clin. Chem. 46 : 319 323.
17. Schmechel, D. et al. 1978. Brain enolases as specific marker of neuronal and glial cells. Science 199 : 313 315.